Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03687710Enrolling by invitation
Alzheimer’s registry for people with memory concerns or risk
This is a research registry that helps doctors compare how different memory and Alzheimer’s risk groups change over time. It may help researchers learn which people are more likely to develop Alzheimer’s and how to better track early changes.
New York, New YorkAges 18–99 - NCT03089827Enrolling by invitation
Tests how a brain imaging tracer spreads in Alzheimer’s risk
This trial uses a radioactive imaging tracer to see how it moves and settles in the brain in people with risk factors for Alzheimer’s disease. It may help researchers understand which people show tracer patterns linked to Alzheimer’s changes.
Winston-Salem, North CarolinaAges 55 years+ - NCT05477862Enrolling by invitation
Improvised music for Alzheimer's anxiety
This study looks at how creating music in the moment (improvisation) affects anxiety and brain function in people with mild to moderate Alzheimer's disease. It may help reduce agitation and improve quality of life.
Chicago, IllinoisAges 55–100 - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT03082755RecruitingPhase 4
Study sleep agitation and restless legs in Alzheimer’s patients
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
Austin, TexasAges 55 years+ - NCT03810794Recruiting
Acupuncture study for people with Alzheimer’s memory problems
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
Shanghai, Shanghai MunicipalityAges 50–85 - NCT04114994Recruiting
Memory testing study for adults 50 and older
This study checks how people’s thinking and memory change over time using a specific cognitive test. It may help researchers understand patterns of memory change and supports future research on brain health.
Miami, FloridaAges 50 years+ - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04902703RecruitingPhase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Aurora, ColoradoAges 60–85 - NCT05295615Recruiting
Pulsed magnetic treatment for mild to moderate Alzheimer’s
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
Hackensack, New JerseyAges 50–100 - NCT05509387Recruiting
Stronger brain stimulation to improve naming in Alzheimer’s
This trial tests whether a stronger form of gentle brain stimulation (tDCS) can help people with mild to moderate Alzheimer’s improve word-finding (naming). If you qualify, you’ll be assessed before and during the study to see whether the stimulation improves naming ability.
Toronto, OntarioAges 50–90 - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT06254469RecruitingPhase 3
PET scan study for memory decline with head injury or Alzheimer's risk
This trial uses a special PET scan tracer to see if it can predict who will get worse over time. It is for people with mild memory or thinking problems that may be linked to past head injuries or early Alzheimer's disease.
Evanston, IllinoisAges 45 years+ - NCT07213700Recruiting
Long-term study on Alzheimer's disease
This study follows people who are either being evaluated for Alzheimer's disease or have already been diagnosed. Researchers want to track their health over many years to better understand the disease and how treatments affect it.
SchwarzachAges Any age - NCT06448975Recruiting
Study of neck surgery for Alzheimer's disease
This trial tests a new surgery on neck lymph vessels to see if it helps people with Alzheimer's. It is for patients aged 60 to 80 with mild to severe Alzheimer's who have had the diagnosis for over a year.
Wuxi, JiangsuAges 60–80 - NCT06523296Recruiting
Antibodies and thinking problems in myasthenia or Alzheimer's
This study looks at whether certain antibodies are linked to memory and thinking problems in people with myasthenia gravis or Alzheimer's disease. It involves a one-time use of leftover spinal fluid from a previous diagnostic test.
Nice, Alpes MaritimesAges 18 years+ - NCT06535308RecruitingPhase 1
Testing a new Alzheimer's drug for moderate disease
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Seoul, Jongno-guAges 19–45 - NCT06566170Recruiting
Donanemab for early Alzheimer's: a real-world study
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
Huntsville, AlabamaAges 60 years+ - NCT06582706RecruitingPhase 1/Phase 2
Vitamin B3 (niacin) for Alzheimer's disease
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Indianapolis, IndianaAges 60–85
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 295 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.